Citations (45)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Nour Faqeer, Rawaa Alrabie, Rand Al-Haddadin & Mohammad Ma’koseh. (2023) Characteristics and predictors of infusion-related reactions to rituximab in patients with B-cell non-Hodgkin lymphoma. Journal of Chemotherapy 0:0, pages 1-8.
Read now
Read now
Rajeev Sandal, Kundan Mishra, Aditya Jandial, Kamal Kant Sahu & Ahmad Daniyal Siddiqui. (2021) Update on diagnosis and treatment of immune thrombocytopenia. Expert Review of Clinical Pharmacology 14:5, pages 553-568.
Read now
Read now
Shiho Ito, Kyoko Miwa, Chiharu Hattori, Tetsuo Aida, Yoshimi Tsuchiya & Kazuhiko Mori. (2021) Highly sensitive in vitro cytokine release assay incorporating high-density preculture. Journal of Immunotoxicology 18:1, pages 136-143.
Read now
Read now
Articles from other publishers (42)
Sahar Dadkhahfar. 2024. Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal. Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal
335
345
.
Nascar Katerine do Carmo, Isadora Soares de Lima, Ana Júlia Machado Miranda, Camila Bariani Veloso Viana, Leonardo Luiz Borges, Wilson de Melo Cruvinel, Carlton Anthony Taft, Vinícius Barreto da Silva & Clayson Moura Gomes. 2024. Trends and Innovations in Energetic Sources, Functional Compounds and Biotechnology. Trends and Innovations in Energetic Sources, Functional Compounds and Biotechnology
301
320
.
Gang Ye, Ruangang Pan, Fan Bu, Jian Zheng, Alise Mendoza, Wei Wen, Lanying Du, Benjamin Spiller, Brian E. Wadzinski, Bin Liu, Stanley Perlman & Fang Li. (2023) Discovery of Nanosota-2, -3, and -4 as super potent and broad-spectrum therapeutic nanobody candidates against COVID-19. Journal of Virology 97:11.
Crossref
Crossref
Jinyu Luo, Zaoqian Zheng & Rongliang Yu. (2023) Analysis of medical malpractice liability disputes related to novel antineoplastic drugs and research on risk prevention and control strategies. PLOS ONE 18:6, pages e0286623.
Crossref
Crossref
Hugo Jourdain, Léa Hoisnard, Emilie Sbidian & Mahmoud Zureik. (2023) Severe Hypersensitivity Reactions at Biosimilar versus Originator Rituximab Treatment Initiation, Switch and Over Time: A Cohort Study on the French National Health Data System. BioDrugs 37:3, pages 397-407.
Crossref
Crossref
Jette A. van Lint, Naomi T. Jessurun, Sander W. Tas, Harald E. Vonkeman, Martijn B. A. van Doorn, Frank Hoentjen, Michael T. Nurmohamed, Eugene P. van Puijenbroek & Bart J. F. van den Bemt. (2023) Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor. BioDrugs.
Crossref
Crossref
Sophia Ly, Dmitry Nedosekin & Henry K. Wong. (2023) Review of an Anti-CD20 Monoclonal Antibody for the Treatment of Autoimmune Diseases of the Skin. American Journal of Clinical Dermatology 24:2, pages 247-273.
Crossref
Crossref
Bianca Galateanu, Alexandra Ioana Pușcașu, Simona Andreea Tircol, Bogdan Cosmin Tanase, Ariana Hudita, Carolina Negrei, George-Traian-Alexandru Burcea-Dragomiroiu, Lucian Negreanu, Ileana Adela Vacaroiu & Octav Ginghină. (2023) Allergy in Cancer Care: Antineoplastic Therapy-Induced Hypersensitivity Reactions. International Journal of Molecular Sciences 24:4, pages 3886.
Crossref
Crossref
You Ao, Zhongbo Wang, Jinghua Hu, Mingguang Yao & Wei Zhang. (2023) Identification of essential genes and immune cell infiltration in rheumatoid arthritis by bioinformatics analysis. Scientific Reports 13:1.
Crossref
Crossref
Ana Muntañola, José María Arguiñano‐Pérez, Julio Dávila, Sonia González de Villambrosia, Cecilia Carpio, Ana Jiménez‐Ubieto & Antonio Salar. (2022) Safety and tolerability of a 90‐minute rapid infusion of Sandoz biosimilar rituximab in B‐cell lymphoproliferative disorders in a real‐world setting. Clinical and Translational Science 16:2, pages 305-312.
Crossref
Crossref
David W. Bearl, Aamir Jeewa, Scott R. Auerbach, Estela Azeka, Christina Phelps, Loren D. Sacks, David Rosenthal & Jennifer Conway. (2022) Clinical approach to mechanical circulatory support in the transplant patient from the Pediatric Heart Transplant Society. Pediatric Transplantation 26:8.
Crossref
Crossref
Timothy G. Chow, Lauren E. Franzblau & David A. Khan. (2022) Adverse Reactions to Biologic Medications Used in Allergy and Immunology Diseases. Current Allergy and Asthma Reports 22:12, pages 195-207.
Crossref
Crossref
Jan Miroslav Hartinger, Vojtech Kratky, Zdenka Hruskova, Ondrej Slanar & Vladimir Tesar. (2022) Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives. Frontiers in Immunology 13.
Crossref
Crossref
Nadia M T Roodenrijs, Paco M J Welsing, Joël van Roon, Jan L M Schoneveld, Marlies C van der Goes, György Nagy, Michael J Townsend & Jacob M van Laar. (2022) Mechanisms underlying DMARD inefficacy in difficult-to-treat rheumatoid arthritis: a narrative review with systematic literature search. Rheumatology 61:9, pages 3552-3566.
Crossref
Crossref
Lawrence SteinmanEdward FoxHans-Peter HartungEnrique AlvarezPeiqing QianSibyl WrayDerrick RobertsonDeRen HuangKrzysztof SelmajDaniel WynnGary CutterKoby MokYanzhi HsuYihuan XuMichael S. WeissJenna A. BoscoSean A. PowerLily LeeHari P. MiskinBruce A.C. Cree. (2022) Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis. New England Journal of Medicine 387:8, pages 704-714.
Crossref
Crossref
Pedro Mendes‐Bastos, Ana Brasileiro, Pavel Kolkhir, Stefan Frischbutter, Jörg Scheffel, Sherezade Moñino‐Romero & Marcus Maurer. (2022) Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions. Allergy 77:8, pages 2355-2366.
Crossref
Crossref
Alex J. Gordon, Aneek Patel, Fang Zhou, Cheng Liu, Amit Saxena, Paula Rackoff & Babak Givi. (2022) Minor Salivary Gland Biopsy in Diagnosis of Sjögren’s Syndrome. OTO Open 6:3.
Crossref
Crossref
Erin Somerville, Kurt Gebauer & Andrew Mclean‐Tooke. (2022) Treatment of pemphigus in Australia: Aligning current practises with global recommendations. Australasian Journal of Dermatology 63:2, pages 190-196.
Crossref
Crossref
Guillaume Le Cosquer, David Ribes, Stanislas Faguer, Muriel Jeune, Laurent Alric, Barbara Bournet & Louis Buscail. (2022) Long-Term Follow-Up and Immunomonitoring of Relapsing Type 1 Autoimmune Pancreatitis Treated With Rituximab. Pancreas 51:5, pages 452-462.
Crossref
Crossref
Jennifer R. Blase, David Frame, Thomas F. Michniacki & Kelly Walkovich. (2022) Case Report: Use of Obinutuzumab as an Alternative Monoclonal Anti-CD20 Antibody in a Patient With Refractory Immune Thrombocytopenia Complicated by Rituximab-Induced Serum Sickness and Anti-Rituximab Antibodies. Frontiers in Immunology 13.
Crossref
Crossref
Nik Krajnc, Gabriel Bsteh, Thomas Berger, Jan Mares & Hans-Peter Hartung. (2022) Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management. Neurotherapeutics 19:3, pages 753-773.
Crossref
Crossref
Chiara Briani & Andrea Visentin. (2022) Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies. Neurotherapeutics 19:3, pages 874-884.
Crossref
Crossref
Daisuke Tsutsumi, Tatsuya Hayama, Katsuhiro Miura, Akihiro Uchiike, Shinya Tsuboi, Susumu Otsuka, Yoshihiro Hatta & Yukinaga Kishikawa. (2021) A novel rituximab administration protocol to minimize infusion-related adverse reactions in patients with B-cell lymphoma. International Journal of Clinical Pharmacy 44:2, pages 366-373.
Crossref
Crossref
Francesco Piazza, Veronica Di Paolo, Greta Scapinello, Sabrina Manni, Livio Trentin & Luigi Quintieri. (2022) Determinants of Drug Resistance in B-Cell Non-Hodgkin Lymphomas: The Case of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia. Frontiers in Oncology 11.
Crossref
Crossref
Despina Fotiou, Foteini Theodorakakou & Efstathios Kastritis. (2022) Monoclonal antibody-based therapies for Waldenström's macroglobulinemia. Leukemia Research Reports 17, pages 100324.
Crossref
Crossref
Maria Chitty-Lopez & Jolan E. Walter. 2022. Allergic and Immunologic Diseases. Allergic and Immunologic Diseases
1431
1446
.
Beate Bittner & Johannes Schmidt. 2022. Formulation and Device Lifecycle Management of Biotherapeutics. Formulation and Device Lifecycle Management of Biotherapeutics
47
83
.
Hani Kushlaf & Yuebing Li. (2021) How does rituximab fit in the treatment algorithm of myasthenia gravis?. Muscle & Nerve 64:6, pages 635-636.
Crossref
Crossref
Maude Plante, Laurence Garneau, Magali Laprise-Lachance, Pierre Lemieux & Michel Dorval. (2021) Impact of Split Dosing the First Rituximab Infusion in Patients with High Lymphocyte Count. Current Oncology 28:5, pages 4118-4128.
Crossref
Crossref
Mitchell EversThies RösnerAnna DünkelJ. H. Marco JansenNiklas BaumannToine ten BroekeMaaike NederendKlara EichholzKatja KlauszKarli ReidingDenis M. Schewe, Christian Kellner, Matthias PeippJeanette H. W. Leusen & Thomas Valerius. (2021) The selection of variable regions affects effector mechanisms of IgA antibodies against CD20. Blood Advances 5:19, pages 3807-3820.
Crossref
Crossref
Elena Treppo, Marco Binutti, Roberto Agarinis, Salvatore De Vita & Luca Quartuccio. (2021) Rituximab Induction and Maintenance in ANCA-Associated Vasculitis: State of the Art and Future Perspectives. Journal of Clinical Medicine 10:17, pages 3773.
Crossref
Crossref
Victoria S. Leung & Yuankai Lin. (2021) Rituximab‐induced acute lympholysis and pancytopenia after COVID‐19 vaccination. Clinical Case Reports 9:8.
Crossref
Crossref
Jocelyn Courville, Loretta Nastoupil, Nitin Kaila, John Kelton, Jeffrey Zhang, Ann Alcasid & Pilar Nava-Parada. (2021) Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar. BioDrugs 35:4, pages 459-468.
Crossref
Crossref
Shuo Zhang, Nan Jiang, Li Wang, Li Zhang, Hua Chen, Mengtao Li & Xiaofeng Zeng. (2021) A modified regimen of low-dose rituximab therapy for patients with refractory immune thrombocytopenia associated with systemic lupus erythematosus. Therapeutic Advances in Chronic Disease 12, pages 204062232110486.
Crossref
Crossref
Hugo Rotkopf, Michaël Lévy, Christiane Copie-Bergman, Jehan Dupuis, Muriel Verlinde-Carvalho, Emmanuel Itti, Charlotte Gagniere, Karim Belhadj, Jenny Tannoury, Fabien Le Bras, Iradj Sobhani, Corinne Haioun & Aurelien Amiot. (2021) Effectiveness and Safety of Subcutaneous Rituximab for Patients With Gastric MALT Lymphoma: A Case–Control Comparison With Intravenous Rituximab. Clinical Lymphoma Myeloma and Leukemia 21:1, pages e32-e38.
Crossref
Crossref
Angelo Bellinvia, Elio Prestipino, Emilio Portaccio, Lorenzo Razzolini, Mattia Fonderico, Roberto Fratangelo, Laura Tudisco, Luisa Pastò & Maria P. Amato. (2020) Experience with rituximab therapy in a real-life sample of multiple sclerosis patients. Neurological Sciences 41:10, pages 2939-2945.
Crossref
Crossref
Leticia Garcia-Montoya, Catalina Villota-Eraso, Md Yuzaiful Md Yusof, Edward M Vital & Paul Emery. (2020) Lessons for rituximab therapy in patients with rheumatoid arthritis. The Lancet Rheumatology 2:8, pages e497-e509.
Crossref
Crossref
Thomas Roux, Savine Vicart, Natalia Shor, Raphaël De Paz, Anne Léger, Caroline Papeix & Elisabeth Maillart. (2020) Multiple cervical dissections after Rituximab. Multiple Sclerosis and Related Disorders 42, pages 102105.
Crossref
Crossref
K. Bigaut & N. Collongues. (2020) Intérêt du rituximab dans les SEP progressives. Pratique Neurologique - FMC 11:1, pages 1-9.
Crossref
Crossref
Hyun Hwa KimMira MoonMin Kyoung ChoKyung Min AhnSoojie ChungDong Yoon KangSuh Young LeeSang-Heon ChoHye-Ryun Kang. (2020) Comparison of one-bag and multibag desensitization protocols for the prevention of rituximab hypersensitivity. Allergy, Asthma & Respiratory Disease 8:3, pages 135.
Crossref
Crossref
Urmi Khanna, Ariana M. Ellis & Anthony P. Fernandez. (2019) Adverse Cutaneous Reactions of Common Biologic Medications for Rheumatic Diseases. Current Treatment Options in Rheumatology 5:4, pages 290-312.
Crossref
Crossref
Soheil Tavakolpour, Samira Alesaeidi, Mohammad Darvishi, Mojtaba GhasemiAdl, Sahar Darabi-Monadi, Meisam Akhlaghdoust, Somayeh Elikaei Behjati & Arash Jafarieh. (2019) A comprehensive review of rituximab therapy in rheumatoid arthritis patients. Clinical Rheumatology 38:11, pages 2977-2994.
Crossref
Crossref